Adaptive Biotechnologies (ADPT) Common Equity (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Common Equity data on file, last reported at $216.3 million in Q1 2026.

• Quarterly Common Equity rose 13.73% year-over-year to $216.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $216.3 million (up 13.73% YoY) and the FY2025 annual result came in at $218.8 million, up 8.05% from the prior year.
• Common Equity fell to $216.3 million in Q1 2026 per ADPT's latest filing, from $218.8 million in the prior quarter.
• The five-year high for Common Equity was $553.3 million in Q1 2022, with the low at $179.5 million in Q2 2025.
• Average Common Equity over 5 years is $321.5 million, with a median of $274.8 million recorded in 2024.
• Year-over-year, Common Equity plunged 39.03% in 2024 and grew 13.73% in 2026.
• Adaptive Biotechnologies' Common Equity stood at $464.1 million in 2022, then tumbled by 33.57% to $308.3 million in 2023, then slumped by 34.32% to $202.5 million in 2024, then climbed by 8.05% to $218.8 million in 2025, then retreated by 1.12% to $216.3 million in 2026.
• Business Quant data shows ADPT's Common Equity at $216.3 million in Q1 2026, $218.8 million in Q4 2025, and $204.3 million in Q3 2025.